Keymed Biosciences Announces 2023 Annual Results and Business Updates

Pipeline Highlights Pipeline Highlights The progress of core pipeline products: Stapokibart (CM310) (IL-4Rα antibody) CMG901/AZD0901 (Claudin 18.2 antibody conjugated) CM313 (CD38 antibody) CM326 (TSLP antibody) Progress of other pipeline products: CM355/ICP-B02 (CD20xCD3 bispecific antibody) CM336 (BCMAxCD3 bispecific antibody) CM350 (GPC3xCD3 bispecific antibody) CM338 (MASP-2 antibody) CM369/ICP-B05 (CCR8 antibody) CM383 (Aβ...

Pipeline Highlights

The progress of core pipeline products:

Stapokibart (CM310) (IL-4Rα antibody)

CMG901/AZD0901 (Claudin 18.2 antibody conjugated)

CM313 (CD38 antibody)

CM326 (TSLP antibody)

Progress of other pipeline products:

CM355/ICP-B02 (CD20xCD3 bispecific antibody)

CM336 (BCMAxCD3 bispecific antibody)

CM350 (GPC3xCD3 bispecific antibody)

CM338 (MASP-2 antibody)

CM369/ICP-B05 (CCR8 antibody)

CM383 (Aβ protofibrils antibody)

Financial and Business Highlights

About Keymed Biosciences Inc.

Keymed Biosciences Inc. (HKEX: 02162) focuses on the urgent unmet clinical needs, and is committed to providing high-quality, affordable, innovative therapies for patients in China and overseas. Keymed was founded by medical and scientific experts from world-renowned universities who have strong experience in the transformation of scientific and technological achievements to commercialization at home and abroad. The core leadership team includes the inventors of the first PD-1 antibody drugs that were pioneered and approved in the United States and China. The Company was listed on the main board of Hong Kong Stock Exchange on July 8, 2021.

To accelerate the efficiency of our research and discovery, we have established a fully-integrated platform encompassing all of the key functions in the biologic drug development. These include target validation, lead molecule discovery and optimization, preclinical evaluation, process development, translational research, clinical development and manufacturing. This integrated platform has enabled us to rapidly and cost-effectively identify, build, expand and advance our diversified pipeline of innovative and differentiated antibody-based therapies, including monoclonal antibodies, antibody drug conjugates (ADCs) and bispecific antibodies.

For more information, please visit www.keymedbio.com.

View original content:https://www.prnewswire.co.uk/news-releases/keymed-biosciences-announces-2023-annual-results-and-business-updates-302099957.html